Tectonic Therapeutic. TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group ...
Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Tenax ...
Kruse from Harvard Medical School. In January, the company shared positive early results from its Phase 1b clinical trial of TX45, its main product candidate. TX45 is a long-acting Fc-relaxin ...
Kruse from Harvard Medical School. In January, the company shared positive early results from its Phase 1b clinical trial of TX45, its main product candidate. TX45 is a long-acting Fc-relaxin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback